TrialPLoS medicine2025

Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China.

Hongru Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.